A06628 Summary:

BILL NOA06628
 
SAME ASNo Same As
 
SPONSORBarclay
 
COSPNSRManktelow, Salka, Lemondes, DeStefano, Miller M, Giglio JM, Blankenbush
 
MLTSPNSR
 
Amd §2803-c, Pub Health L
 
Designates an individual to be notified in the case of dose or brand change for psychotropic medication.
Go to top    

A06628 Actions:

BILL NOA06628
 
03/23/2021referred to health
01/05/2022referred to health
05/10/2022held for consideration in health
Go to top

A06628 Committee Votes:

HEALTH Chair:Gottfried DATE:05/10/2022AYE/NAY:19/7 Action: Held for Consideration
GottfriedAyeByrneNay
GalefAyeMcDonoughNay
DinowitzAyeByrnesNay
CahillAyeAshbyNay
PaulinAyeSalkaNay
CymbrowitzAyeJensenNay
GuntherAyeGandolfoNay
Rosenthal L Aye
HevesiAye
SteckAye
AbinantiAye
BraunsteinAye
SolagesAye
Bichotte HermelAye
SayeghAye
Rosenthal D Aye
McDonaldAye
ReyesAye
Gonzalez-RojasAye

Go to top

A06628 Floor Votes:

There are no votes for this bill in this legislative session.
Go to top

A06628 Text:



 
                STATE OF NEW YORK
        ________________________________________________________________________
 
                                          6628
 
                               2021-2022 Regular Sessions
 
                   IN ASSEMBLY
 
                                     March 23, 2021
                                       ___________
 
        Introduced  by  M. of A. BARCLAY, MANKTELOW, SALKA, LEMONDES, DeSTEFANO,
          M. MILLER, J. M. GIGLIO, BLANKENBUSH -- read once and referred to  the
          Committee on Health
 
        AN  ACT  to  amend  the public health law, in relation to designating an
          individual to be notified in the case of  dose  or  brand  change  for
          psychotropic medication

          The  People of the State of New York, represented in Senate and Assem-
        bly, do enact as follows:
 
     1    Section 1. Subdivision 3 of section 2803-c of the public health law is
     2  amended by adding a new paragraph s to read as follows:
     3    s. (i) Pursuant to regulations promulgated by the commissioner,  every
     4  patient  shall  have the right to designate an individual to be notified
     5  in the event that the facility reduces the dose or changes the brand  or
     6  form  of  the patient's psychotropic medication. Such notification shall
     7  include a warning listing possible side effects and  drug  interactions,
     8  including  side effects upon discontinuation of such drugs. Notification
     9  shall be made in writing, and shall not be effective  until  receipt  of
    10  the written consent of the designated individual. In the case of a grad-
    11  ual  dose  reduction,  a  designee  shall check a box acknowledging such
    12  designee has been given a copy of the rights pertaining to gradual  dose
    13  reductions.
    14    (ii)  For  the  purposes  of this paragraph, "psychotropic medication"
    15  means a medication that is administered for  the  purpose  of  affecting
    16  brain  activities associated with mental processes and behavior, includ-
    17  ing, but not limited to, anti-psychotics, anti-depressants, anxiolytics,
    18  sedatives and hypnotics.
    19    § 2. This act shall take effect on the one hundred eightieth day after
    20  it shall have become a law.
 
 
         EXPLANATION--Matter in italics (underscored) is new; matter in brackets
                              [ ] is old law to be omitted.
                                                                   LBD03002-02-1
Go to top